Corcept醫療 CORT 深 滬
等待開盤 03-26 09:30:00 美东时间
40.47
+6.650
+19.66%
華盛通- 最 高50.40
- 今 開34.15
- 成交量 1172.13万股
- 最 低 33.99
- 昨 收 33.82
- 總市值 43.05亿
- 52周最高 91.00
- 市盈率 靜 49.46
- 換手率 11.02%
- 52周最低 28.6601
- 委 比 97.55%
- 總股本 1.06亿
- 歷史最高 117.33
- 量 比 6.73
- 振 幅 48.52%
- 歷史最低 1.27
- 每 手 1
- 風險率 16.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Amazon To Rally Around 49%? Here Are 10 Top Analyst Forecasts For Wednesday
Top analysts change outlook for top names. Citigroup, Tigress Fin, Piper Sandler, Morgan Stanley, HC Wainwright, Susquehanna, Raymond James and Goldman Sachs adjust price targets for companies like Braze, Amazon, TELA Bio, Smithfield Foods, Corcept Therapeutics, TechnipFMC, Phillips 66, and KB Home. See all changes at benzinga.com/analyst-stock-ratings.
54分钟前
What's Behind The Jump In Corcept Therapeutics Stock?
Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) are soaring Wednesday after the FDA approved a treatment for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
今天 00:06
Corcept granted FDA nod for cancer therapy
Shares of Corcept Therapeutics (CORT) surged before a trading halt in the morning hours on Wednesday after the U.S. Food and Drug Administration (FDA) approved its cancer therapy, relacorilant. Specif...
03-25 22:55
FDA Approves Relacorilant With Nab-paclitaxel For Platinum-resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relacorilant-nab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or
03-25 22:39
新浪财经ESG：Corcept医疗 MSCI（明晟）ESG评级调升至BB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:17
Brent Hits $110, Rate-Hike Fears Hammer Stocks And Gold: What's Moving Markets Friday?
U.S. stocks fall to four-month lows as oil surges above $110, Treasury yields spike, and markets price a 50% chance of a Fed rate hike by October.
03-21 01:36
Corcept rises after insider buy worth over $3M
Corcept Therapeutics (CORT) traded higher on Friday after the company’s board member Leonard Baker Jr. disclosed that he purchased shares of the Korlym maker in a transaction worth more than $3M earli...
03-20 23:00
Wolf Haldenstein files securities class action against Corcept Therapeutics over relacorilant statements
Wolf Haldenstein files securities class action against Corcept Therapeutics over relacorilant statements A securities class action lawsuit was filed against Corcept on behalf of investors who purchased the company’s securities between Oct. 31, 2024 and Dec. 30, 2025. The complaint alleges the compan
03-16 20:21
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $60
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and lowers the price target from $67 to $60.
02-25 19:54
